Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...